The Food and Drug Administration continues to approve cancer therapies amid the COVID-19 pandemic. Here are five approvals that patients with cancer may have missed.
The Food and Drug Administration (FDA) has approved several therapies as of late, even amid the COVID-19 pandemic, and it’s easy to have missed an approval that matters to patients. That’s why CURE® rounded up coverage of the most recent approvals that patients may have missed.
FDA Approves Rubraca for Metastatic Castration-Resistant Prostate Cancer That Expresses a BRCA Gene Mutation
The PARP inhibitor Rubraca represents a new treatment option for men with metastatic castration-resistant prostate cancer that expresses a BRCA gene mutation and has been previously treated with hormonal therapy and taxane-based chemotherapy. READ MORE.
FDA Approves Opdivo-Yervoy Combination For Treatment of Metastatic NSCLC
The Food and Drug Administration approved the combination of Opdivo-Yervoy immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer that do not have certain genomic tumor aberrations. READ MORE.
FDA Approves Tecentriq Immunotherapy For Certain Non-Small Cell Lung Cancers
Tecentriq is approved as an initial treatment for non-small cell lung cancer that has spread and expresses the protein PD-L1 but does not have alterations in the EGFR or ALK genes. READ MORE.
FDA Approves Lynparza for Certain Pretreated Patients with Metastatic Prostate Cancer
The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate). READ MORE.
FDA Approves Qinlock for Patients with Pretreated, Advanced GIST
The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors. READ MORE.
To keep up with all of CURE’s FDA coverage sign up for our email list here.